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Abstract
In the present study antileukemic enzyme L-asparaginase (ASNase) and catalase (as a model enzyme) were modified in
solid-phase with activated polyethylene glycol (PEG ) by using ligand-immobilized affinity column systems L-asparagine-2
Sepharose CL-4B and Procion red-Sepharose CL-4B, respectively. Studies on change of specific activity with modification
time showed negligible differences between batches of modified catalase. Modification of ASNase for 1 h resulted in 50.2%
recovery of the specific activity and the attachment of 69 molecules of PEG per molecule of ASNase forming ‘PEGylated2
ASNase’. Sequential modification of ASNase by activated PEG and heparin resulted in coupling of about nine molecules of
heparin per molecule of PEGylated ASNase. Intravenous (i.v.) administration of PEG -modified ASNase showed prolonged2
presence in the blood circulation and no adverse effects or symptoms of anaphylaxis were observed in presensitized mice.
  2003 Elsevier B.V. All rights reserved.
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1 . Introduction tion of proteins with polyethylene glycol (PEG), a
linear, non-toxic, non-immunogenic and amphipathic
Chemical modification of proteins became com- polymer has been studied as a potential means to add
mon in the late 1950s. The techniques were original- unique properties to proteins. The technique of
ly developed for use in the structural analysis of modification with polyethylene glycol has opened a
proteins. Since the late 1970s, many articles on the new avenue towards reduction of the immuno-
chemical modification of proteins with synthetic reactivity and prolonged the clearance time of
macromolecules have been published [1]. Modifica- foreign protein drugs used in biomedical applications
[2–4].
The term ‘site-specific modification’ is used to
describe the methods for chemical modification of
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sites of enzymes and antibodies are located in the biology, including: (a) binding of site-specifically
protein moieties hence, the immobilization of the biotinylated enzymes to membrane immobilized
glycoproteins through their carbohydrate residues do streptavidin bridge; (b) fusion protein technology
not only stabilize the protein conformation but also coupled with affinity tags on membranes; and (c)
provide better access of the substrate to the active site-directed mutagenesis to introduce a cysteine into
sites [5,6]. a protein with subsequent SH-specific coupling to the
In one such study, Petkov et al. [7] achieved a membrane support [11].
successful immobilization of glucose oxidase via Increased circulatory half-life of some proteins
activation of its carbohydrate residues by oxidation upon modification with PEG or other high molecular
with galactose oxidase. The oxidized enzyme was mass polymers may be attributed to the decreased
coupled to hydrazine derivatives of O-a-D-galactosyl clearance by glomerular filtration by the kidney
Sepharose-H1000 or Sepharose-4B. Glucose oxidase [12,13]. Conjugation of PEG to proteins caused a
immobilized by this procedure showed higher activi- great increase in the size of the protein, presumably
ty than the glucose oxidases modified using other due to the hydration of PEG. Increasing the extent of
immobilization procedures. modification increased the size of the protein, there-
Likewise, site-specific and site-directed modifica- by decreasing the amount lost due to glomerular
tion of antibodies may be achieved by chemical or filtration.
enzymatic oxidation of the carbohydrate residues Another possible mechanism for the prolonged
located remote from the binding sites of the anti- half-life in the circulation includes the different
body, on the Fc fragment. Immobilization through actions of various proteases, such as trypsin and
this region does not usually impair the immunologi- chymotrypsin, on the unconjugated form of ASNase.
cal activity of the antibody [8]. A third potential mechanism for PEG-asparaginase’s
The protection of the activity of the enzyme prolonged half-life may be related to its decreased
during the immobilization procedure by the presence clearance by the reticuloendothelial system, which is
of competitive inhibitor has been reported by several responsible for the clearance of foreign proteins
researchers. In one such study, Blanco et al. [9] [14,15].
showed that multipoint covalent attachment of en- In order to accomplish effective modification of a
zyme in the presence of competitive enzyme inhib- bioactive agent with PEG, a balance must be main-
itor to activated (aldehyde generated) support pre- tained between the number of PEG chains (of a given
served the enzyme in fully active form. The inhibitor molecular mass) which are required to prevent
bound on the active centre of the enzyme protects the immunogenicity, and the decrease in enzyme activity
enzyme from distorting conformational changes by resulting from the number of PEGs bound to or in
multipoint covalent attachment to aldehyde agarose proximity of active sites. In situations where stan-
gels. dard PEG modification may block too many active
In addition to protecting active sites, a different sites on the target macromolecule, a higher molecu-
application of oriented immobilization of enzymes lar mass, branched PEG (U-PEG) would, in concept,
was demonstrated by Turkova et al. [10]. In this be better because it would require only half the
study, site specific crosslinking of antichymotrypsin attachment sites to provide an equal coverage [16].
with glutaraldehyde was achieved after biospesific PEG-conjugated proteins are expensive due to
adsorption of enzyme to natural inhibitor, antilysine their difficult and long purification steps. Ultrafiltra-
immobilized on Sepharose 4B. This antilysine– tion is the major method to eliminate the unbound
chymotrypin crosslinked complex was further used methoxy polyethylene glycol (mPEG) but it has a
as biospecific adsorbent for isolation of immuno- tendency to block the pores of the membrane filter
globulin G against antigenic sites outside of active because of its random coil structure that is well
site of chymotrypsin. hydrated in aqueous solution. With mPEGs having an
There are several approaches to oriented immobili- MW of 5000 Da or greater, it was noted that the
zation of enzymes using the power of molecular ultrafiltration membrane was blocked rapidly owing
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to clogging of the pores by free mPEG [17]. The Facility of Gulhane Military Medical Academy
major drawback of pressure-driven membrane pro- (Ankara, Turkey).
cesses, ultrafiltration in particular, is the build up of All the other chemicals used were of analytical
material at the membrane–solution interface [18]. grade.
In this study an alternative enzyme modification
was tested; catalase and L-asparaginase were im-
mobilized on an affinity matrix by adsorption on a 2 .2. Activation of PEG
biosorbent and to this structure activated poly-
ethylene glycol chains were added. This novel Activated PEG, 2-4-bis(O-methoxy polyethylene
method offers a means of protection of active sites glycol)-6-chloro-s-triazine) (PEG ), was prepared2
during a modified process by orienting the enzyme from monomethoxypolyethylene glycol according to
active site towards the solid-phase and the presence the method of Ona et al. [19]. Monomethoxy-
of the solid support offers a convenient way of polyethylene glycol (110 g) was dissolved in 500 ml
removing the unused reactive reagents without a of anhydrous benzene. The solution was refluxed in
need for excessive dialysis or ultrafiltration. Sequen- the presence of granular Molecular Sieves 4 A for 6
tial modification of asparaginese first with PEG and h to remove water. After cooling, zinc oxide (50 g)
then with heparin also served the purpose of inves- and cyanuric chloride (1.85 g) were added, and the
tigating the suitability of solid-phase modification to mixture was refluxed for 53 h. The resulting mixture
controlled attachment of various polymers. In vivo was diluted with 500 ml of benzene and filtered. The
studies were performed to study the pharmacody- product (PEG ) was precipitated by addition of2
namic behaviour and immunogenicity of solid-phase petroleum ether twice the volume of the solution
modified L-asparaginase preparations. followed by drying under vacuum to obtain 108 g of
activated PEG.
2 . Experimental 2 .3. Activation of heparin
2 .1. Chemicals Heparin was activated according to method by
Wissink et al. [20]. Heparin (15 mg) was dissolved
Monomethoxy polyethylene glycol (PEG, MW in an aqueous solution of carbodiimide (0.8 mM)
5000), bovine liver catalase (EC 1.11.1.6, 4000 and N-hydroxysuccinimide (0.5 mM). The final pH
units /mg solid), L-asparaginase (Escherichia coli, was adjusted to 5.6 and the solution was stirred for
EC 3.5.1.1, 155 units /mg protein, in 50% glycerol), 10 min at room temperature. The solution was
malic dehydrogenase (MDH, EC 1.1.1.37, porcine dialyzed for 30 min against distilled water (500 ml,
heart, 600 units /mg protein) and glutamic oxaloace- pH 5.6) and used immediately for enzyme conjuga-
tate dehydrogenase (GOT, EC 2.6.1.1, 309 units /mg tion.
protein), 1,4-butanediol diglycidyl ether (BDGE),
carbodiimide (1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide hydrochloride) (EDC), cyanuric chlo- 2 .4. Solid-phase oriented modification of catalase
ride, Sepharose CL 4-B, heparin (porcine intestinal on Procion red-Sepharose
mucosa, Grade I-A) trinitrobenzene sulfonate
(TNBS), and Procion Red H-E 3B were purchased Procion red-Sepharose CL-4B conjugate was pre-
from Sigma (St. Louis, MO, USA). pared according to the method of Stellwagen et al.
Nessler’s reagent was purchased from Aldrich [21]. Wet Sepharose CL-4B (20 g) in distilled water
(Milwaukee, USA). Toluidine blue was from Merck (70 ml) was mixed with Procion red HE-3B (200
(Darmstadt, Germany). mg) dissolved in distilled H O (20 ml). The mixture2
Balb /C mice were obtained from the Animal Care was stirred with a glass rod for 5 min. Into the slurry,
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NaCl (10 ml, 20% (w/v)) was added and stirred for a (4 l, 0.6 N) solution containing sodium borohydride
further 30 min at room temperature. Finally, NaOH (0.08 g) [22]. The activation was allowed to proceed
(0.5 ml, 5 M) was added to the mixture and at room temperature (RT) for 15 h in a 0.5 l flask in
incubated for 3 days while stirring on a magnetic a rotary evaporator. The activated gel was recovered
stirrer. Procion red-Sepharose CL-4B was collected by vacuum filtration, washed seven times with water
on a sintered glass filter and washed sequentially (1.5 l), and coupled to L-asparagine by the reaction
with an excess of deionized water, NaCl (1 M), urea of the gel with L-asparagine (20 g) in sodium
(4–8 M) and distilled water. carbonate buffer (0.5 M, 0.35 l, pH 8.5). The
coupling reaction was allowed to proceed at room
temperature for 15 h with slow rotation in the rotary
2 .4.1. Adsorption of catalase on Procion red- evaporator. After the coupling step, the gel was
Sepharose washed seven times with water (1.5 l) and stored in
Catalase solution (5 ml, 1 mg/ml) in phosphate sodium azide (0.02%).
buffer (10 mM, pH 7.0) was circulated for 1 h using
a peristaltic pump through a column (1310 cm) 2 .5.1. Adsorption of L-asparaginase on activated
packed with Procion red-Sepharose CL-4B. Enzyme matrix
not adsorbed onto the conjugate beads was washed Wet asparagine-Sepharose CL-4B (5 g) was
by phosphate buffer (PB) (10 mM, pH 7.0). packed into an affinity column ((1310 cm, Amer-
sham Pharmacia Biotech, Sweden) and equilibrated
with phosphate buffer (10 mM, pH 7.0). L-As-
2 .4.2. Solid phase PEG modification paraginase solution (5 ml, 0.6 mg) was circulated by2
Cyanuric chloride activated PEG (25 mg) in a peristaltic pump through the column for 1 h.
borate buffer (5 ml, 10 mM, pH 9.0) was circulated Unadsorbed enzyme was washed away with phos-
through the column at a flow-rate of 1.5 ml /min phate buffer (10 mM, pH 8.5) until no protein

using a peristaltic pump (Master Flex , Cole Parmer appeared in the wash (about 30 ml).
Instruments, USA). Unconjugated PEG molecules2
were washed with PB (30 ml). 2 .5.2. Solid phase PEG modification2
Activated PEG (25 mg) was dissolved in borate
buffer (5 ml, 10 mM, pH 9.5) and circulated through
2 .4.3. Desorption of modified catalase the affinity column for 1 h at 17 8C. Unconjugated
In order to elute the solid-phase-modified catalase, PEG molecules were removed by phosphate buffer2
2 M NaCl solution in PB (10 mM, pH 7.0), was (10 mM, pH 7.0) from the column.
circulated through the system for 1 h. Finally, the
eluted enzyme was dialyzed overnight against PB 2 .5.3. Desorption of PEG -modified asparaginase2
(10 mM, pH 7.0). NaCl solution (0.5 M) containing L-asparagine (20
The number of PEG molecules coupled to the mM) was circulated through the affinity column to2
´-amino groups of catalase was calculated from the desorb the adsorbed enzyme until absorbance of the
difference in the free amino contents of the un- enzyme in eluent became steady (about 35 min).
modified enzyme (a native catalase molecule con- The number of PEG molecules coupled to2
tains 112 amino groups) and that of the modified ´-amino groups of asparaginase was calculated from
enzyme. the difference in the amino content of the unmodified
enzyme (a native asparaginase molecule contains 92
amino groups) and that of the modified enzyme.
2 .5. PEG modification of ASNase on2
L-asparagine-Sepharose 2 .6. Sequential solid-phase modification of ASNase
first with PEG and then with heparin2
Sepharose CL-4B was activated by reaction with
1, 4-butanediol diglycidyl ether (40 ml) and NaOH Solid phase PEG modification of ASNase was2
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Fig. 1. Successive solid-phase modification of L-asparaginase.
done as described in Section 2.5. For sequential (25 ml) was mixed with H O (3 ml, 15 mM in 502 2
coupling of activated heparin (Fig. 1), column was mM phosphate buffer, pH 7) and the decrease in
washed with 30 ml distilled water (pH was adjusted absorbance in 2–3 min at 25 8C was recorded with a
to 5.6 with HCl) after PEG modification. Then, 5 UV–Vis spectrophotometer (Shimadzu, Model2
ml of dialyzed aqueous active heparin solution (20 2100). The specific activity, U/mg protein, was
mg, pH 5.6) was circulated through the column for calculated using the extinction coefficient for H O2 2
21 2130 min. Desorption of PEG and heparin conjugated of 0.0447 mM cm from the equation given2
ASNase was achieved by circulating 4 ml sodium below
chloride solution (0.5 M, containing 20 mM L-as-
Specific Activity (U/mg protein)5 (DA /min)240paragine) for 30 min. The modified ASNase solution
21 21 21was dialyzed overnight in PBS at 4 8C. (3025 ml)(0.0447) (25 ml) (mg prot. in 25 ml)
2 .7. Measurement of catalase and ASNase activity 2 .7.2. Specific activity of L-asparaginase in situ
and in vivo
2 .7.1. Specific activity of catalase In situ L-asparaginase activities were measured by
The activity of catalase was determined spectro- Nessler’s method. The assay procedure is based on
photometrically by measuring the decrease in ab- direct Nesslerization of ammonia [24]. Enzyme
sorbance of H O at 240 nm [23]. Enzyme solution solution (10–100 ml) was added to Tris–HCl (pH2 2
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8.5, 50 mM) in a final volume of 1.5 ml. The h to complete the reaction. After adding SDS (250
reaction was started with addition of L-asparagine ml, 10%) and HCl (125 ml, 1 M), the absorbance of
solution (0.5 ml, 10 mM, in 50 mM Tris–HCl, pH the solution at 335 nm was measured. A standard
8.5) and allowed to proceed for 5–60 min at 37 8C. curve was obtained using glycine solutions (0–1
The incubation was stopped with trichloroacetic acid mM). The degree of modification is obtained by
(0.5 ml, 15%) and the volume was adjusted to 4.5 ml dividing the number of modified free amino groups
with distilled water. Nessler’s reagent (0.5 ml) was by the total number of amino groups in the un-
added, and the mixture was allowed to stand at room modified enzyme molecule.
temperature for 15 min, and then the absorbance at
500 nm was measured with UV–Vis spec-
trophotometer. 2 .9. Determination of heparin concentration
The extinction coefficient of NH Cl (used as a4
21
standard ammonia) was found to be 0.1383 mM The amount of heparin conjugated to asparaginase
21
cm . was estimated by the Toluidine blue reaction as
L-asparaginase specific activity (Unit) was calcu- described by Smith et al. [27]. PEG -Heparin-ASN-2
lated as: (DA /min) /(0.1383) /mg. ase sample (0.1 ml) was added into Toluidine blue500
To measure L-asparaginase activity in the serum of solution (2.5 ml, 0.005%, 0.01 N HCl containing
mice, coupled enzyme assay was used due to the 0.2% NaCl) in a test tube. The mixture was vortexed
higher sensitivity of the method compared with vigorously for 30 s. It was diluted with NaCl (0.2%)
Nessler’s method [25]. The enzyme mixture was to a total volume of 5 ml and agitated by a vortex
prepared by mixing glycerol (100 ml, 87%), Tris– mixer for 30 s. Hexane (5 ml) was then added to
HCl buffer (pH 8.45, 50 ml, 0.5 M), NADH (50 each tube and the tubes were shaken vigorously for
mg), a-ketoglutaric acid (50 mg), GOT (180 U), another 30 s to separate the heparin–dye complex
MDH (110 U) and the volume was adjusted to 500 formed. Aqueous solution (0.5 ml) was mixed with
ml with distilled water. Asparaginase containing ethanol (2.5 ml) and the absorbance was measured at
plasma (50 ml) was added into this enzyme-coupled 621 nm by using UV–visible spectrophotometer. To
activity assay mixture (2.25 ml) and incubated for 15 construct a standard curve with a concentration range
min at 37 8C. Then, 250 ml 10 mM L-asparagine in of approximately 10–70 mg of heparin, varying
Tris–HCl buffer, pH 8.5, was added and the reduc- amounts of heparin in saline solution (2.5 ml 0.2%)
tion in absorbance of NADH was recorded at 340 nm were prepared and mixed with the dye solution (2.5
using UV–visible spectrophotometer. ml). For the assessment of the number of heparin
The concentration of native and modified enzymes molecules bound on each asparaginase molecule, the
were calculated by the use of Lowry protein de- average molecular masses for heparin and asparagin-
termination method [26]. ase were assumed to be 19 000 and 136 000 Da,
respectively.
2 .8. Determination of the degree of modification of
enzymes with PEG 2 .10. Determination of in vivo half-life of ASNase2
preparations
The degree of modification with PEG was de-2
termined through quantifying the amino groups in Studies to measure the residence of modified and
the modified enzyme by reaction with trinitrobenzene unmodified asparaginase in the circulation were
sulfonate (TNBS). An enzyme solution (250 ml, 0.5 undertaken using female Balb-C mice. The animals
mg protein /ml) was mixed with sodium bicarbonate were housed in the Animal Care Facility (METU), in
buffer (250 ml, 0.5 M, pH 8.5) and then an aqueous an air-conditioned room with a 12 h light /12 h dark
solution of trinitrobenzene sulfonate (250 ml, 0.1%) cycle. PEG modified L-asparaginase (0.5 ml, 1.2 U)2
was added. The mixture was incubated at 40 8C for 2 or unmodified free asparaginase (0.5 ml, 30 U) in
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 PBS was injected to the dilated lateral vein of mice.
By using opposite lateral vein, blood samples were
collected into heparin (10 ml, 5 mg/ml) containing
plastic microtubes. After centrifugation, 50 ml of
plasma was collected and added into enzyme assay
mixture (2.25 ml) (for coupled enzyme activity
assay). After incubating plasma in enzyme assay
mixture 15 min at 37 8C, substrate solution (0.25 ml,
10 mM) was added and the reaction was started for
asparaginase activity measurement.
2 .11. Antigenicity of ASNase preparations
For toxicity studies, four Balb-C mice for solid-
phase PEG-modified and three for unmodified ASN-
ase, were sensitized with subcutaneous injections Fig. 2. Specific activity (--) and number of coupled PEG2
molecules (-j-) at specified times of solid-phase PEG modi-of 100 mg of unmodified, and PEG -modified ASN- 22
fication of catalase on Procion red-Sepharose. (n52 for specificase on days 0, 10, and 20 [28]. On day 30, animals
activity and n53 for attached PEG determination. Modifications
were challenged with the same dose of free and
were performed at 17 8C with a PEG flow-rate of 1.5 ml /min).2PEG-modified enzyme given by intravenous injec-
tion through their tail vein. Deaths and symptoms of
hypersensitivity were recorded.
Specific activity vs. modification time showed small
differences in batches. As seen from the error bars of
3 . Results and discussion specific activity which correspond to two indepen-
dent solid-phase preparations, the batch differences
3 .1. PEG modification of catalase on Procion are quite small. This indicated that solid-phase2
red-Sepharose CL-4B modification yields quite homogenous PEG –protein2
conjugates at the end of the process. Other advan-
For solid-phase modification of catalase, a specific tages of solid-phase enzyme modification are pre-
affinity column aimed to protect the active site of the sented in Table 1.
enzyme was prepared and the enzyme was modified
with activated polyethylene glycol. Procion Red H-E 3 .2. PEG modification of ASNase2
3B dye molecule was reported to bind the empty
NADPH cofactor space near the catalytic site of In order to monitor the kinetics of enzyme ad-
catalase (some subunits of catalase were detected to sorption, and possible changes during PEG modi-2
have no cofactor) [29]. As seen in Fig. 2, the number fication of solid-phase ASNase, a flow-through cell
of attached PEG increased almost linearly with the was connected to the outlet of an affinity column.2
reaction time. At the end of a 1 h reaction time with Fig. 3 shows a rapid adsorption of the enzyme on the
PEG , 75 molecules of PEG were conjugated per affinity matrix (removal from circulating solution);2 2
catalase molecule (75 per 112 amino groups oc- adsorption was accomplished within a few minutes
cupied). In the same figure it is shown that as the and there was no change in the unadsorbed protein
conjugation of PEG increases, the specific activity level after the 10th min indicating the efficiency of2
of catalase decreases in almost linear fashion. Some the system. It was seen that during the modification
subunits in tetrameric catalase molecule may not be with PEG the enzyme was not desorbed or did not2
protected by the affinity matrix during PEG modi- leak from its affinity matrix. This indicates a strong2
fication due to the globular structure of enzyme. adsorption by L-asparaginase on the matrix.
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T able 1
Advantages and disadvantages of solid-phase oriented enzyme modification and free enzyme modification methods
Solid-phase oriented enzyme modification Free enzyme modification
Active sites of enzymes can be protected As the reaction proceeds randomly in nature, active sites can
from modification by active polymer be harmed by the modification. Enzyme activity may be lost
By keeping column temperature and flow-rate Modification level is adjusted by a ratio of
constant, batch differences in enzyme modification enzyme functional group/active reagent. As
can be avoided. Washing of active reagents is instantaneous, the reaction can not be stopped instantaneously,
for that reason the level of modification is constant at batch differences by random modification is
specified conditions. quite possible.
Modification control is easy. The modification can be stopped By changing reaction medium (sudden pH changes, neutralizing
by simple column washing. chemicals) modification can be stopped, but it is not instantaneous.
Modified enzyme can be desorbed from column in pure form. Since there are active reagents and reaction by-products,
the purification process requiring long and tedious purification
and concentration steps.
Fig. 4 presents the desorption profile of L-as- 2). The specific activities of the unmodified and
paraginase after modification with PEG from the modified asparaginase were 147.0 U/mg and 73.82
affinity matrix by 0.5 M NaCl containing 20 mM U/mg protein, respectively.
asparagine. Desorption was achieved in about 10 PEG modification of asparaginase on asparagine-2
min. Since the desorption solution was circulated in Sepharose-CL-4B was achieved with the attachment
a closed loop, the equlibration of the desorbed of about 69 PEG molecules per asparaginase mole-2
protein with the circulating solution required some cule with a retention of 50.2% specific activity for a
time and within 30 min removal was completed. The 1 h of reaction time. Enzyme was partially protected
number of PEG molecules attached per molecule of from inactivation by PEG modification process by2 2
asparaginase was determined using TNBS. A 1 h binding it to affinity column. Inada et al. [15],
solid-phase modification resulted in the conjugation reported 10% residual specific activity after 57%
of 69.6 PEG molecules per asparaginase molecule modification of asparaginase (52 of 92 amino groups2
and 50.2% of the original specific activity was on the enzyme were modified) with cyanuric chlo-
recovered in the desorbed asparaginase eluate (Table ride activated PEG. This result clearly shows that in
 
 
Fig. 3. Adsorption profile of ASNase (--) on asparagine-Sepha- Fig. 4. Desorption profile of PEG -modified L-asparaginase (--)2
rose column (Test temperature: 17 8C, Enzyme Flow Rate: 1.5 from asparagine-Sepharose by 0.5 M NaCl containing 20 mM
ml/min). L-asparagine. (Flow rate: 1.5 ml /min).
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T able 2
Changes in the activity and specific activity of asparaginase during solid-phase modification to PEG-ASNase
Steps Total activity % Activity Specific activity % Specific activity
in solid-phase (Unit) (Unit /mg)
modification
Before adsorption 78.8 100 147.0 100
Supernatant 6.0 7.6 – –
Desorbed PEG-ASNase 18.6 23.6 73.8 50.25
Washing 15.6 19.8 – –
Solid-phase modification conditions: PEG (5 mg/ml, pH 9.5) at 17 8C and 1 h circulation.2
the present study the asparagine-Sepharose matrix result (56 vs. 50 h) their preparation had only 10% of
efficiently protected the active sites of the asparagin- the original specific activity whereas our preparation
ase against the detrimental effects of PEG modi- retained its specific activity to a level of 50.2% of2
fication by orienting the active site of the subunit the original. The high specific activity in our prepa-
away from the mobile phase and towards the solid ration must be the result of the differences in the
matrix. The active form of asparaginase is composed PEGylation procedures. It seems that asparagine-
of four identical subunits, A, B, C, and D [30]. Since Sepharose CL-4B affinity column significantly
the enzyme is tetrameric and globular it is not protects the active sites of ASNase.
possible to attach all the subunits to the affinity Sequential PEG and heparin conjugation was2
matrix. Consequently, the active sites of some achieved on affinity matrix of L-asparaginase. As-
subunits may not be protected against PEG modi- paraginase modified for 1 h with PEG and then2 2
fication and the inactivation of those subunits is conjugated with heparin had about nine molecules of
probably the cause of the decrease in the specific heparin per asparaginase molecule. The residence
activity. half-lives (t ) of unmodified, PEG -conjugated1 / 2 2
ASNase, and PEG -heparin conjugated ASNase in2
3 .3. Determination of in vivo half life of ASNase
 preparations
One of the aims of this study was to increase the
half-life and prevent the toxicity of L-asparaginase in
the circulation by modifying with polyethylene gly-
col and heparin on a solid-phase affinity matrix,
L-asparagine-Sepharose CL-4B. To assess the phar-
macokinetic properties of PEG modified ASNase2
and PEG -heparin conjugated ASNase these prepara-2
tions were introduced to the blood circulation of
Balb /C mice. Unmodified ASNase showed a very
sharp clearance from the circulation as shown in Fig.
5. Slightly less than 50% of the activity remained
after 10 h of circulation, a value very close to the
half-life of 11 h reported in the literature [24].
Solid-phase PEG modified ASNase, however,2
showed a prolonged clearance from the circulation
(Fig. 5). Even after 2 days, more than 50% of the Fig. 5. Residual activity of unmodified (--), solid-phase PEG2
activity was still in circulation. modified (-j-), and solid-phase PEG and heparin conjugated2
Although the half-life obtained with PEG modi- (-m-) ASNase in blood serum of mice. Injected doses: Native2
ASNase: 30 U, PEG -ASNase: 1.2 U, PEG -Hep-ASNase: 1.3 U.fied ASNase by Inada et al. [15] was similar to our 2 2
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the circulation were 10, 50 and 25 h, respectively. adsorbed enzyme by various polymers to change
Compared with only-PEG conjugate, however, the physical and biological properties of enzymes.2
residence time of the ASNase modified by PEG and2
heparin was decreased (half-lives 50 h with PEG-
ASNase whereas 25 h with PEG-heparin-ASNase). 4 . Conclusion
Since, heparin is a negatively charged host-polymer
and some cell types have heparin receptors, heparin Solid-phase oriented enzyme modification employ-
attachment probably rendered asparaginase molecule ing catalase as a model enzyme was performed on
more recognizable by endothelial cells and poly- the affinity medium Procion red-Sepharose. A sig-
morphonuclear leukocytes. Nevertheless, the experi- nificant amount of PEG was bound on the enzyme
ment showed the suitability of solid-phase modi- after 1 h reaction time (75 molecules of PEG per2
fication to sequential conjugation of polymers to 112 amino groups) and the results were reproducible.
change the biological properties of enzyme mole- The retention of specific activity was at the level of
cules and target these pharmaceutical proteins to 46.5%
specific body sites. The same approach was then tested on the anti-
In conclusion, solid-phase PEG modification of leukemic enzyme asparaginase using asparagine-2
ASNase produced a very long circulatory-half life Sepharose-CL-4B system as the solid support. A
compared to unmodified ASNase preparations and very significant level of occupation of the available
heparin conjugation decreased this to some extent. amine groups was achieved with the attachment of
about 69 PEG molecules per asparaginase molecule2
3 .4. Antigenicity testing for ASNase preparations with a retention of 50.2% specific activity within 1 h
of reaction time.
In order to test the antigenicity, modified and Both these enzymes revealed that site-directed
native ASNase were introduced to mice by three immobilization followed by PEG attachment retained
subcutaneous (s.c) and one intravenous (i.v.) in- a significantly higher fraction of the activity of the
jections (challenge). Subcutaneous injections were enzyme in question
for the sensitization of the animals before the i.v The literature reveals that when L-asparagine was
injection. When the native ASNase was injected, two modified with PEG 5000 activated by succinimidyl
of the three mice showed typical anaphylaxis and succinate, the PEG-enzyme could retain only 30% of
died within 30 min. Upon injection of modified the original activity of nonmodified asparaginase and
ASNase, however, no adverse effects or symptoms the extent of modification of amino groups in the
of anaphylaxis were observed. These results indicate molecule was determined to be 50 amino groups
that solid-phase modification of enzymes on their [31].
affinity matrix prevented hypersensitivity reactions In another study L-asparaginase from Escherichia
by covering antigenic sites of the enzyme by nonim- coli was modified with 2,4-bis(O-methoxy-
munogenic PEG molecules and made them more polyethylene glycol)-6-chloro-s-triazine (activated2
suitable for pharmaceutical applications. PEG ) [32]. The PEG -modified asparaginase re-2 2
This study indicated that modification of enzymes tained approximately 30% (73 IU/mg of protein) of
by solid-phase oriented and non-random modification the enzymic activity of the native enzyme, while it
method presents important advantages both in practi- had almost completely lost its immunoreactivity
cal applications (therapeutic) and basic enzymology: towards anti-asparaginase antibodies.
the accuracy of modification level (number of cou- E. coli asparaginase was modified with poly(N-
pled polymers), protection of active sites from vinylpyrrolidone-co-maleic anhydride) approximate-
reactive polymers, desorption of pure modified en- ly 69% of amino groups were modified but it
zyme from the affinity column thereby, not requiring retained only 8.3% of the native L-asparaginase
extensive time consuming purification steps, and activity [33].
enabling a flexibility in subsequent modification of All these studies had low yields of modification
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and low retention of enzymatic activity revealing that of Natural and Applied Sciences (Grant METU AFP-
site direction and modification on solid supports is a 99-06-02-23).
very effective way of enzyme modification.
ASNase could also be successfully and sequential-
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